CHMO

CHIMERIC OPT MAR24 [CHMO]

1 day chart

About CHMO

Chimeric Therapeutics Limited (CHM) is an Australian clinical stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. Products under development by the group are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies.

Buy Australian shares starting with CHMO. Invest today with a CHESS-sponsored investing platform!

Sector

CEO

Industry

Website

chimerictherapeutics.com

Market Capitalisation

$16M

Price-earnings ratio

-0.02

Dividend yield

NaN%

High today

$0.00

Low today

$0.00

Open price

$0.00

52-week high

$0.04

52-week low

$0.00

Announcements

CHMO FAQs

Can I buy CHMO shares through Stake, an investing platform like CommSec, Selfwealth or Superhero?

Yes, the Stake platform allows you to buy CHMO shares and over 8,000 stocks and ETFs across the ASX and Wall St.

How much is one share of CHIMERIC OPT MAR24 [CHMO]?

One share of CHIMERIC OPT MAR24 [CHMO] is valued at $0.00.

What is the ticker symbol for CHIMERIC OPT MAR24 [CHMO]?

The ticker symbol for CHIMERIC OPT MAR24 [CHMO] is CHMO.

How do I buy CHMO shares in Australia?

To buy CHMO stocks in Australia you'll need to open an account with an investing platform like Stake.
To do so follow these steps:

Sign up in minutes, all you need is some I.D.
Choose Stake AUS
Deposit directly into your Stake wallet and you're ready to invest in CHMO

What is the 52-week high for CHIMERIC OPT MAR24 [CHMO] stock?

The CHIMERIC OPT MAR24 [CHMO] 52-week high stock price is $0.04.

What is the 52-week low for CHIMERIC OPT MAR24 [CHMO] stock?

The CHIMERIC OPT MAR24 [CHMO] 52-week low stock price is $0.00.

What is the market capitalisation of CHIMERIC OPT MAR24 [CHMO] CHMO?

As of 26/09/2023 CHIMERIC OPT MAR24 [CHMO] has a market cap of $16M.

Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.